Chester County News and Community Website
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) reported third-quarter 2025 financial results and highlighted steady progress across its two clinical-stage DNA damage response (DDR) programs, citing emerging signs of …
Aprea Advances Dual DDR Programs as Early Signals of Drug Activity Strengthen Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) announced encouraging early clinical data from its ongoing Phase 1 ACESOT-1051 trial evaluating APR-1051, a first-in-class WEE1 kinase inhibitor, in patients with …
Aprea Therapeutics Reports Early Signs of Activity in APR-1051 Cancer Trial Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) announced that new data from its ongoing oncology programs will be featured in two poster presentations at the 2025 EORTC-NCI-AACR International Conference …
Aprea Therapeutics to Present New Data on APR-1051 and ATRN-119 at EORTC-NCI-AACR Conference Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) reported encouraging early clinical results from its two lead oncology programs while narrowing its quarterly loss, according to second-quarter 2025 financial results …
Aprea Reports Positive Early Cancer Trial Results, Maintains Cash Runway Into 2026 Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) has revealed new preclinical findings and a clinical update on APR-1051, an innovative oral WEE1 inhibitor being studied for the treatment of …
Aprea Therapeutics Announces Promising Data on APR-1051 for HPV-Positive Cancers Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) announced a key milestone in its ACESOT-1051 clinical trial, as the first patient with HPV-positive (HPV+) head and neck squamous cell carcinoma (HNSCC) …
Aprea Therapeutics Advances ACESOT-1051 Clinical Trial with Key Patient Dosing Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE), a clinical-stage biopharmaceutical company, shared its financial results for 2024 and provided a progress update on its lead programs aimed at advancing cancer …
Aprea Therapeutics Reports 2024 Financial Results and Updates on Clinical Innovations Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) has entered into a Material Transfer Agreement (MTA) with MD Anderson Cancer Center to advance preclinical studies of its WEE1 kinase inhibitor, APR-1051. …
Aprea Therapeutics Teams Up with MD Anderson for Preclinical HNSCC Research Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) has announced significant advancements in its intellectual property portfolio, reinforcing the company’s leadership in the development of DNA Damage Response (DDR) therapeutics for …
Aprea Therapeutics Strengthens Patent Portfolio to Advance Oncology Innovation Read More DOYLESTOWN, PA — Aprea Therapeutics (Nasdaq: APRE) has announced a key update in its ongoing Phase 1/2a ABOYA-119 clinical trial for ATRN-119, aimed at treating advanced solid tumors with DNA damage …
Aprea Therapeutics Updates ABOYA-119 Trial with Twice Daily Dosing Read More